S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Ford Stock Going Forward After Big Earnings Flop
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Indian tycoon Adani hit by more losses, calls for probe
Ford, Starbucks fall; Clorox, Gilead Sciences rise
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Ford Stock Going Forward After Big Earnings Flop
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Indian tycoon Adani hit by more losses, calls for probe
Ford, Starbucks fall; Clorox, Gilead Sciences rise
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Ford Stock Going Forward After Big Earnings Flop
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Indian tycoon Adani hit by more losses, calls for probe
Ford, Starbucks fall; Clorox, Gilead Sciences rise
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Ford Stock Going Forward After Big Earnings Flop
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Indian tycoon Adani hit by more losses, calls for probe
Ford, Starbucks fall; Clorox, Gilead Sciences rise
NASDAQ:ALIM

Alimera Sciences - ALIM Stock Forecast, Price & News

$2.84
-0.10 (-3.40%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.78
$2.95
50-Day Range
$2.12
$3.58
52-Week Range
$2.03
$7.92
Volume
33,368 shs
Average Volume
13,142 shs
Market Capitalization
$19.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.75

Alimera Sciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
137.7% Upside
$6.75 Price Target
Short Interest
Healthy
0.40% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.44mentions of Alimera Sciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.33) to ($0.67) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

334th out of 1,029 stocks

Pharmaceutical Preparations Industry

155th out of 501 stocks

ALIM stock logo

About Alimera Sciences (NASDAQ:ALIM) Stock

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.

Receive ALIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alimera Sciences and its competitors with MarketBeat's FREE daily newsletter.

ALIM Stock News Headlines

Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
7 Stocks That Could Implode at Any Moment
Alimera Sciences Q3 2022 Earnings Preview
See More Headlines
Receive ALIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alimera Sciences and its competitors with MarketBeat's FREE daily newsletter.

ALIM Company Calendar

Last Earnings
11/14/2022
Today
2/04/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALIM
Employees
145
Year Founded
2003

Price Target and Rating

Average Stock Price Forecast
$6.75
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$4.50
Forecasted Upside/Downside
+137.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-4,370,000.00
Pretax Margin
-34.10%

Debt

Sales & Book Value

Annual Sales
$59.03 million
Book Value
($3.15) per share

Miscellaneous

Free Float
6,094,000
Market Cap
$19.88 million
Optionable
Optionable
Beta
1.34

Social Links


Key Executives

  • Richard S. EiswirthRichard S. Eiswirth
    President, Chief Executive Officer & Director
  • Philip John AshmanPhilip John Ashman
    COO & SVP-Commercial Operations Europe
  • Russell L. Skibsted
    Chief Financial Officer & Senior Vice President
  • Christopher S. Visick
    Secretary, Vice President & General Counsel
  • David Dyer
    Chief Retina Specialist













ALIM Stock - Frequently Asked Questions

Should I buy or sell Alimera Sciences stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ALIM shares.
View ALIM analyst ratings
or view top-rated stocks.

What is Alimera Sciences' stock price forecast for 2023?

2 analysts have issued 12-month price targets for Alimera Sciences' stock. Their ALIM share price forecasts range from $4.50 to $9.00. On average, they predict the company's stock price to reach $6.75 in the next year. This suggests a possible upside of 137.7% from the stock's current price.
View analysts price targets for ALIM
or view top-rated stocks among Wall Street analysts.

How have ALIM shares performed in 2023?

Alimera Sciences' stock was trading at $2.71 on January 1st, 2023. Since then, ALIM shares have increased by 4.8% and is now trading at $2.84.
View the best growth stocks for 2023 here
.

Are investors shorting Alimera Sciences?

Alimera Sciences saw a drop in short interest during the month of January. As of January 15th, there was short interest totaling 21,500 shares, a drop of 9.7% from the December 31st total of 23,800 shares. Based on an average daily trading volume, of 14,300 shares, the short-interest ratio is currently 1.5 days. Currently, 0.4% of the company's shares are short sold.
View Alimera Sciences' Short Interest
.

When is Alimera Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our ALIM earnings forecast
.

How were Alimera Sciences' earnings last quarter?

Alimera Sciences, Inc. (NASDAQ:ALIM) issued its quarterly earnings data on Monday, November, 14th. The biopharmaceutical company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.37) by $0.38. The biopharmaceutical company earned $13.60 million during the quarter, compared to analysts' expectations of $15.60 million.

When did Alimera Sciences' stock split?

Shares of Alimera Sciences reverse split on the morning of Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 14th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is Rick Eiswirth's approval rating as Alimera Sciences' CEO?

2 employees have rated Alimera Sciences Chief Executive Officer Rick Eiswirth on Glassdoor.com. Rick Eiswirth has an approval rating of 100% among the company's employees. This puts Rick Eiswirth in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alimera Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include EyePoint Pharmaceuticals (EYPT), OPKO Health (OPK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN), AngloGold Ashanti (AU), SSR Mining (SSRM), ADMA Biologics (ADMA) and Cellectar Biosciences (CLRB).

What is Alimera Sciences' stock symbol?

Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."

Who are Alimera Sciences' major shareholders?

Alimera Sciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include James R Largent, John Philip Jones, Philip Ashman, Richard S Eiswirth Jr and Stanley Morgan.
View institutional ownership trends
.

How do I buy shares of Alimera Sciences?

Shares of ALIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alimera Sciences' stock price today?

One share of ALIM stock can currently be purchased for approximately $2.84.

How much money does Alimera Sciences make?

Alimera Sciences (NASDAQ:ALIM) has a market capitalization of $19.88 million and generates $59.03 million in revenue each year. The biopharmaceutical company earns $-4,370,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis.

How many employees does Alimera Sciences have?

The company employs 145 workers across the globe.

How can I contact Alimera Sciences?

Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The official website for the company is www.alimerasciences.com. The biopharmaceutical company can be reached via phone at (678) 990-5740, via email at scottg@coreir.com, or via fax at 678-990-5744.

This page (NASDAQ:ALIM) was last updated on 2/4/2023 by MarketBeat.com Staff